Fortune October 4, 2023
Brendan Case, Shelly Banjo, Bloomberg

Walmart says it’s already seeing an impact on shopping demand from people taking the diabetes drug Ozempic, Wegovy and other appetite-suppressing medications.

“We definitely do see a slight change compared to the total population, we do see a slight pullback in overall basket,” John Furner, the chief executive officer of Walmart’s sprawling US operation, said in an interview Wednesday. “Just less units, slightly less calories.”

The Bentonville, Arkansas-based retailer is studying changes in sales patterns using anonymized data on shopper populations. It can look at the purchasing changes among people taking the drug and can also compare those habits to similar people who aren’t taking the shots. Furner said it’s too early to draw any definitive conclusions about the...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Patient / Consumer, Provider, Retailer
AI, Omnichannel and Social Commerce: Inside the 2024 D2C Transformation
How AI Is Quietly Transforming E-Commerce Search And Discovery
Walmart's '24 healthcare exit: 10 notes
What big retailers did in healthcare in 2024
How Trauma-Informed Design Principles Can Be Health-Ful for All of Us – Learning from IKEA

Share This Article